CANTON, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
management will present at the following investor conferences in November:
- The Jefferies London Healthcare Conference on Thursday, November 17th at 12:40 p.m. GMT at the Waldorf Hilton London
Hotel
- The 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30th at 12:00 p.m. EST at the Lotte New York
Palace Hotel
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. For Important Safety
Information including full prescribing information visit: http://www.xtampzaer.com/.
Contact: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com
